Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

详细信息    查看全文

• 作者：Britta Auel (1)
  Hartmut Goldschmidt (2)
  Thomas Geer (3)
  Thomas M. Moehler (2)
  Uwe Platzbecker (4)
  Ralph Naumann (5)
  Igor Blau (6)
  Mathias H?nel (7)
  Wolfgang Knauf (8)
  Holger Nückel (9)
  Hans-Jürgen Salwender (10)
  Christof Scheid (11)
  Katja Weisel (12)
  Marcus Gorschlüter (1)
  Axel Glasmacher (1)
  Ingo G. H. Schmidt-Wolf (1)
  
• 关键词：Myeloma ; Thalidomide ; Idarubicin ; Vinorelbine ; Dexamethasone
• 刊名：Indian Journal of Hematology and Blood Transfusion
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：28
• 期：2
• 页码：67-76
• 全文大小：336KB
• 参考文献：1. Barlogie B, Smith L (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-356 CrossRef
  2. Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, Schmidt-Wolf IGH, Gieseler F (1997) Oral idarubicin, dexamethason and vincristine (VID) in the treatment of multiple myeloma. Leukemia 11:22-6 CrossRef
  3. Cook G, Sharp RA, Tansey P, Franklin IM (1996) A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br J Haematol 93:931-34 CrossRef
  4. Harousseau Jl, Dammacco F, San-Miguel J et al (1999) An alternative treatment for relapsed/resistant multiple myeloma (MM): vinorelbin (VRL) plus high-dose dexamethasone (DEX): two phase II studies. Proc Annu Meet Am Soc Clin Oncol 18 (abstract)
  5. Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, Schmidt-Wolf IG, Gieseler F (2004) Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. Haematologica 89(3):371-73
  6. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschlüter M (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132:584-93 CrossRef
  7. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ (2007) The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 92:1149-150 CrossRef
  8. Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D, Glasmacher A, Schmidt-Wolf IG, Blau IW, Martin H, Salwender H, Haenel A, Sonneveld P, Goldschmidt H (2007) Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 21:1294-299 CrossRef
  9. Ong F, Hermans J, Noordijk EM, Kliun-Nelemans JC (1995) Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma. Ann Hematol 70:19-4 CrossRef
  10. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-84 CrossRef
  11. Bladé J, Samson D, Reece D, Apperley J, Bj?rkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoetic stem cell transplantation. Br J Haematol 102:1115-123 CrossRef
  12. Glasmacher A, Hahn C, Fiegl M et al (2000) VRID as induction therapy in patients with refractory multiple myeloma. Blood 100:385b
  13. Cavenagh JD, Oakervee H, UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces (2003) Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 120:18-6
  14. Singhal S, Mehta J, Desikan R et al (2003) Antitumor activity of thalidomide alone or with dexamethasone for multiple myeloma. N Engl J Med 341:1565-571 CrossRef
  15. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 a study of 169 patients. Blood 98:492-94 CrossRef
  16. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL (2006) Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 91:862-63
  17. Kyriakou C, Thomson K, D’Sa S, Flory A, Hanslip J, Goldstone AH, Yong KL (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 129:763-70 CrossRef
  18. Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, Wood LL, Smith GG, Cripe LD, Abonour R (2007) Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a hoosier oncology group trial, HEM01-1. Oncologist 12:99-06 CrossRef
  19. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H (2001) Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98:3846-848 CrossRef
  20. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (2001) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-7 CrossRef
  21. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV (2003) Response rate, durability of response and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78:34-9 CrossRef
  22. Alexanian R, Weber D, Giralt S, Delasalle K (2002) Consolidation therapy of multiple myeloma with thalidomide–dexamethasone after intensive chemotherapy. Ann Oncol 13:1116-119 CrossRef
  23. Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro AM, Varettoni M, Gay F, Morra E, Lazzarino M (2009) Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leuk Res 33:145-49 CrossRef
  24. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, Triolo S, Gallo E, Pileri A, Boccadoro M (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-03
  
• 作者单位：Britta Auel (1)
  Hartmut Goldschmidt (2)
  Thomas Geer (3)
  Thomas M. Moehler (2)
  Uwe Platzbecker (4)
  Ralph Naumann (5)
  Igor Blau (6)
  Mathias H?nel (7)
  Wolfgang Knauf (8)
  Holger Nückel (9)
  Hans-Jürgen Salwender (10)
  Christof Scheid (11)
  Katja Weisel (12)
  Marcus Gorschlüter (1)
  Axel Glasmacher (1)
  Ingo G. H. Schmidt-Wolf (1)
  
  1. Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany
  2. Universit?tsklinikum, Heidelberg, Germany
  3. Diakonie-Krankenhaus, Schw?bisch-Hall, Germany
  4. Universit?tsklinikum, Dresden, Germany
  5. Stiftungsklinikum, Koblenz, Germany
  6. Charite, Berlin, Germany
  7. Klinikum, Chemnitz, Germany
  8. Praxis, Frankfurt, Germany
  9. Universit?tsklinikum, Essen, Germany
  10. Asklepios Klinik Altona, Hamburg, Germany
  11. Universit?tsklinikum, K?ln, Germany
  12. Universit?tsklinikum, Tübingen, Germany
  
• ISSN：0974-0449

文摘

Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.